The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02699528
Recruitment Status : Unknown
Verified September 2016 by Natan Watemberg, Meir Medical Center. Recruitment status was: Recruiting
To assess wether methylphenidate reduces the prevalence of primary nocturnal enuresis in children with attention deficit disorder
Condition or disease
Attention Deficit Hyperactivity DisorderEnuresis
Children aged 5 - 10 years newly diagnosed with attention deficit hyperactivity disorder who report primary nocturnal enuresis, Investigators will obtain baseline data (from parents/caregivers) on their sleep habits and enuresis characteristics by questionnaire. After 6 weeks of methylphenidate therapy, prescribed for the attention deficit, a new questionnaire will be filled.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
5 Years to 10 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Children aged 5 - 10 years receiving a new diagnosis of attention deficit hyperactivity disorder
New diagnosis of attention deficit hyperactivity disorder
History of primary nocturnal enuresis
Normal neurological examination
Anatomical abnormality of the genitourinary system
Concommitant treatment, pharmacological/behavioral for enuresis